CClinicalTrials.gg
CompletedNCT06462586Updated Jul 24, 2026

Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania

A Phase 3 interventional study of Lumateperone and Placebo in Bipolar Disorder, Manic, sponsored by Intra-Cellular Therapies, Inc.. Completed at 42 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Intra-Cellular Therapies, Inc. · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
354
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

Read the detailed description

The study will be conducted in 3 phases:

  • Screening Period (up to 1 week) during which patient eligibility will be assessed.
  • Double-blind Treatment Period (3 weeks) during which all eligible patients will be randomized to receive lumateperone 42 mg or placebo in 1:1 ratio.
  • Safety Follow-up Period (1 week) during which all patients will return to the clinic for a safety follow-up visit
02

Conditions studied

  • Bipolar Disorder, Manic

Browse trials for

03

In context

Bipolar Disorder

1,601 studies on the registry are indexed under Bipolar Disorder; 254 are open to participants now.

This study's enrollment of 354 is above the median of 64 across 1,223 interventional studies indexed under Bipolar Disorder.

Browse Bipolar Disorder studies →

Lead sponsor

Intra-Cellular Therapies, Inc. is the lead sponsor of 40 studies on the registry; 12 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 10 (43%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Able to provide written informed consent before the initiation of any study specific procedures;
  2. Male or female inpatient, between the ages of 18 and 75 years, inclusive;
  3. Meets the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM 5) criteria for bipolar I disorder with a current episode of mania or mania with mixed features with or without psychotic symptoms, as confirmed by a trained and Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT);
  4. YMRS total score ≥ 20 and a score of at least 4 on two of the following YMRS items: irritability, speech, content, and disruptive/aggressive behavior at Screening and Baseline;
  5. Hospitalized voluntarily before Screening or admitted to inpatient unit at Visit 1 with a primary diagnosis of mania but not > 14 days before Screening. Hospital admission must be a result of the current manic episode.

Exclusion criteria

Exclusion Criteria:

  1. Has a current primary DSM 5 psychiatric diagnosis other than bipolar disorder. These include:

    1. Schizophrenia, schizoaffective disorder, or other psychotic disorders;
    2. Dementia or other cognitive disorders;
    3. Intellectual disability;
    4. Moderate or severe substance use disorder (excluding for nicotine);
  2. Experiencing first manic episode;
  3. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during the course of his/her participation in the study or

    1. At Screening, the patient scores "yes" on Items 4 or 5 in the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening; or
    2. At Screening, the patient has had 1 or more suicidal attempts within 2 years prior to Screening; or
    3. At Baseline, the patient scores "yes" on Items 4 or 5 in the Suicidal Ideation section of the C-SSRS since the Screening Visit; or
    4. At Screening or Baseline, scores ≥ 4 on Item 10 (suicidal thoughts) on the rater administered Montgomery-Åsberg Depression Rating Scale (MADRS); or
    5. Considered to be an imminent danger to himself/herself or others.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
354 participants (actual)

Study arms

  • Experimental
    Lumateperone 42 mg

    Lumateperone 42 mg capsules

    Drug: Lumateperone

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • DrugLumateperone

    Lumateperone 42 mg capsules administered orally, once daily

  • DrugPlacebo

    Matching capsules administered orally, once daily

06

What researchers measure

Primary outcomes

  1. Young Mania Rating Scale (YMRS)

    The YMRS is an 11-item, clinician-administered mania rating scale designed to assess the severity of manic symptoms. Four of the YMRS items are rated on a 0 to 8 scale, with the remaining 7 items rated on a 0 to 4 scale. The total score ranges from 0 to 60 with a higher score indicating increased severity of manic symptoms.

    Time frame: Week 3

Secondary outcomes

  1. Clinical Global Impression Scale-Severity (CGI-S)

    The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Week 3

07

Study locations

42 sites
  • Clinical Site
    Rogers, Arkansas 72758, United States
  • Clinical Site
    Bellflower, California 90706, United States
  • Clinical Site
    Culver City, California 90230, United States
  • Clinical Site
    Garden Grove, California 92845, United States
  • Clinical Site
    Lemon Grove, California 91945, United States
  • Clinical Site
    Montclair, California 91763, United States
  • Clinical Site
    Hallandale, Florida 33009, United States
  • Clinical Site
    Hialeah, Florida 33016, United States
  • Clinical Site
    Miami, Florida 33184, United States
  • Clinical Site
    Miami Gardens, Florida 33056, United States
  • Clinical Site
    Miami Lakes, Florida 33016, United States
  • Clinical Site
    Miami Springs, Florida 33166, United States
  • Clinical Site
    Orlando, Florida 32807, United States
  • Clinical Site
    Atlanta, Georgia 30324, United States
  • Clinical Site
    Atlanta, Georgia 30338, United States
  • Clinical Site
    Decatur, Georgia 30030, United States
  • Clinical Site
    Savannah, Georgia 31405, United States
  • Clinical Site
    Shreveport, Louisiana 71101, United States
  • Clinical Site
    Marlton, New Jersey 08053, United States
  • Clinical Site
    North Canton, Ohio 44720, United States
  • Clinical Site
    Austin, Texas 78701, United States
  • Clinical Site
    Austin, Texas 78754, United States
  • Clinical Site
    DeSoto, Texas 75115, United States
  • Clinical Site
    Lovech, 5500, Bulgaria
  • Clinical Site
    Rousse, Bulgaria
  • Clinical Site
    Sofia, 1377, Bulgaria
  • Clinical Site
    Stara Zagora, 6000, Bulgaria
  • Clinical Site
    Veliko Tarnovo, 5000, Bulgaria
  • Clinical Site
    Vratsa, 3000, Bulgaria
  • Clinical Site
    Split, 21000, Croatia
  • Clinical Site
    Zagreb, 10000, Croatia
  • Clinical Site
    Zagreb, 10090, Croatia
  • Clinical Site
    Guwahati, Assam 781032, India
  • Clinical Site
    Mangalore, Karnataka 575018, India
  • Clinical Site
    Mysore, Karnataka 570001, India
  • Clinical Site
    Nashik, Maharashtra 422005, India
  • Clinical Site
    Ludhiana, Punjab 141001, India
  • Clinical Site
    Belgrade, 11000, Serbia
  • Clinical Site
    Kovin, 26220, Serbia
  • Clinical Site
    Kragujevac, 34000, Serbia
  • Clinical Site
    Novi Kneževac, 23330, Serbia
  • Clinical Site
    Novi Sad, 21000, Serbia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06462586
Lead sponsor
Intra-Cellular Therapies, Inc.
Responsible party
Sponsor
First posted
Jun 17, 2024
Start date
Jun 19, 2024
Primary completion
Feb 24, 2026
Completion
Mar 5, 2026
Last update
Jul 24, 2026

Study contacts

Intra-Cellular Therapies, Inc. Clinical Trial
study director · Intra-Cellular Therapies, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion